» Articles » PMID: 35853863

Increased Neutralization and IgG Epitope Identification After MVA-MERS-S Booster Vaccination Against Middle East Respiratory Syndrome

Abstract

Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.

Citing Articles

Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models.

Tscherne A, Meyer Zu Natrup C, Kalodimou G, Volz A Methods Mol Biol. 2024; 2860:297-340.

PMID: 39621276 DOI: 10.1007/978-1-0716-4160-6_20.


Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach.

Weskamm L, Tarnow P, Harms C, Huchon M, Raadsen M, Friedrich M iScience. 2024; 27(8):110470.

PMID: 39148710 PMC: 11325358. DOI: 10.1016/j.isci.2024.110470.


Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus.

Muller-Krauter H, Mezzacapo J, Kluver M, Baumgart S, Becker D, Fathi A Med Microbiol Immunol. 2024; 213(1):6.

PMID: 38722338 PMC: 11082005. DOI: 10.1007/s00430-024-00789-w.


MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.

Mayer L, Weskamm L, Fathi A, Kono M, Heidepriem J, Krahling V NPJ Vaccines. 2024; 9(1):20.

PMID: 38278816 PMC: 10817990. DOI: 10.1038/s41541-023-00801-z.


A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.

Kubinski M, Beicht J, Zdora I, Biermann J, Puff C, Gerlach T Front Immunol. 2023; 14:1182963.

PMID: 37153588 PMC: 10160477. DOI: 10.3389/fimmu.2023.1182963.


References
1.
Wang L, Shi W, Chappell J, Joyce M, Zhang Y, Kanekiyo M . Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018; 92(10). PMC: 5923077. DOI: 10.1128/JVI.02002-17. View

2.
Okba N, Raj V, Widjaja I, GeurtsvanKessel C, de Bruin E, Chandler F . Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. Emerg Infect Dis. 2019; 25(10):1868-1877. PMC: 6759241. DOI: 10.3201/eid2510.190051. View

3.
Song F, Fux R, Provacia L, Volz A, Eickmann M, Becker S . Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol. 2013; 87(21):11950-4. PMC: 3807317. DOI: 10.1128/JVI.01672-13. View

4.
Ying T, Du L, Ju T, Prabakaran P, Lau C, Lu L . Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014; 88(14):7796-805. PMC: 4097770. DOI: 10.1128/JVI.00912-14. View

5.
Nilsson C, Godoy-Ramirez K, Hejdeman B, Brave A, Gudmundsdotter L, Hallengard D . Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses. 2013; 30(3):299-311. PMC: 3938943. DOI: 10.1089/AID.2013.0149. View